Clinical Trial Update: Pioglitazone in Thyroid Cancers [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pioglitazone in thyroid cancers harboring the PAX8-PPARgamma fusion gene has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Pioglitazone (Actos) (pioglitazone)

Snippet

Sponsor: University of Michigan | Conditions: Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene | Phase 2 | Status: COMPLETED | Results posted: 2017-10-26